[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fQNqudxuoZLIA-Tv8Sn6Hh6IIE_bgLpfQujlmfmy0Tj8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":80,"rows":87},"Norwegian University of Science and Technology",[4],488,false,68,20,145799,31,397,[14,16,19,22,25,27,30,32],{"name":15,"count":11},"Obesity, Morbid",{"name":17,"count":18},"Obesity",30,{"name":20,"count":21},"Stroke",10,{"name":23,"count":24},"Cardiovascular Diseases",9,{"name":26,"count":24},"Mental Disorders",{"name":28,"count":29},"Atrial Fibrillation",8,{"name":31,"count":29},"Polycystic Ovary Syndrome",{"name":33,"count":29},"Cancer",[35,40,45,50,55,60,64,68,72,76],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT03540420","Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer","2024-04-01","Atezolizumab",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT03640624","Multidisciplinary Treatment of Chronic Vulvar Pain","2024-11-10","Multidisciplinary treatment",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT03944876","Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Cluster Headache","2025-09","Botulinum toxin type A",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT02904291","Bariatric Surgery and Pharmacokinetics of Amlodipine","2026-05","Amlodipine",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT03497156","Bariatric Surgery and Pharmacokinetics of Lercanidipine","2026-10","Lercanidipine",{"nctId":61,"briefTitle":62,"date":58,"intervention":63},"NCT03460327","Bariatric Surgery and Pharmacokinetics of Candesartan","Candesartan",{"nctId":65,"briefTitle":66,"date":58,"intervention":67},"NCT03476551","Bariatric Surgery and Pharmacokinetics of Hydrochlorothiazide","Hydrochlorothiazide",{"nctId":69,"briefTitle":70,"date":58,"intervention":71},"NCT03476525","Bariatric Surgery and Pharmacokinetics of Fluoxetine","Fluoxetine",{"nctId":73,"briefTitle":74,"date":58,"intervention":75},"NCT03497143","Bariatric Surgery and Pharmacokinetics of Lamotrigine","Lamotrigine",{"nctId":77,"briefTitle":78,"date":58,"intervention":79},"NCT03535376","Bariatric Surgery and Pharmacokinetics of Valsartan","Valsartan",[81,82,83,84,85,86],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[88,154,177,205,223,241,282,326,357,381,399,422,441,459,480,498,516,534,552,570,591,612,630,651,672,693,714,735,756,777,798,819,846,864,890,914,940,966,984,1011,1029,1053,1078,1113,1145,1163,1188,1215,1233,1257,1283,1301,1327,1345,1370,1397,1415,1439,1457,1480,1513,1536,1562,1580,1605,1623,1645,1671,1689,1712,1733,1751,1769,1793,1819,1837,1863,1881,1906,1924,1946,1971,1996,2014,2040,2058,2076,2094,2144,2170,2202,2220,2245,2269,2293,2311,2337,2355,2377,2399,2426,2444,2462,2484,2508,2526,2550,2573,2595,2619],{"intervention":89,"totalTrials":90,"cells":91},"Botulinum Toxin Type A",5,{"EARLY_PHASE1":92,"PHASE1":95,"PHASE2":97,"PHASE3":139,"PHASE4":150,"NA":152},{"trials":93,"activeCount":94},[],0,{"trials":96,"activeCount":94},[],{"trials":98,"activeCount":94},[99,110,120,130],{"nctId":100,"briefTitle":101,"status":102,"phases":103,"primaryCompletion":104,"completion":104,"start":105,"enrollment":21,"conditions":106,"interventions":109},"NCT02662972","Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Trigeminal Neuralgia. Safety Issues.","COMPLETED",[82,83],"2018-11-01","2016-05",[107,108],"Trigeminal Neuralgia","Headache Disorders",[89],{"nctId":111,"briefTitle":112,"status":113,"phases":114,"primaryCompletion":115,"completion":115,"start":116,"enrollment":9,"conditions":117,"interventions":118},"NCT02035397","Intragastric Injections of Botox for the Treatment of Obesity","UNKNOWN",[83],"2022-12","2014-02",[15],[89,119],"Saline solution",{"nctId":121,"briefTitle":122,"status":102,"phases":123,"primaryCompletion":124,"completion":124,"start":125,"enrollment":11,"conditions":126,"interventions":128},"NCT03462290","Botox Injections for Patients With Persistent Facial Pain",[83],"2021-11-23","2018-05-01",[127],"Facial Pain",[129],"botulinum toxin type A",{"nctId":131,"briefTitle":132,"status":102,"phases":133,"primaryCompletion":134,"completion":134,"start":135,"enrollment":21,"conditions":136,"interventions":138},"NCT02259075","Botox Injection in Treatment of Chronic Migraine",[82,83],"2016-03","2015-02",[137],"Migraine Disorders",[89],{"trials":140,"activeCount":149,"soonestReadout":48},[141],{"nctId":46,"briefTitle":47,"status":142,"phases":143,"primaryCompletion":48,"completion":48,"start":144,"enrollment":145,"conditions":146,"interventions":148},"RECRUITING",[84],"2019-11-01",112,[147],"Cluster Headache",[49],1,{"trials":151,"activeCount":94},[],{"trials":153,"activeCount":94},[],{"intervention":39,"totalTrials":149,"cells":155},{"EARLY_PHASE1":156,"PHASE1":158,"PHASE2":160,"PHASE3":171,"PHASE4":173,"NA":175},{"trials":157,"activeCount":94},[],{"trials":159,"activeCount":94},[],{"trials":161,"activeCount":149,"soonestReadout":38},[162],{"nctId":36,"briefTitle":37,"status":163,"phases":164,"primaryCompletion":38,"completion":165,"start":166,"enrollment":167,"conditions":168,"interventions":170},"ACTIVE_NOT_RECRUITING",[83],"2027-04-01","2018-07-31",212,[169],"Small-cell Lung Cancer",[39],{"trials":172,"activeCount":94},[],{"trials":174,"activeCount":94},[],{"trials":176,"activeCount":94},[],{"intervention":178,"totalTrials":149,"cells":179},"ExPlas",{"EARLY_PHASE1":180,"PHASE1":182,"PHASE2":184,"PHASE3":199,"PHASE4":201,"NA":203},{"trials":181,"activeCount":94},[],{"trials":183,"activeCount":94},[],{"trials":185,"activeCount":149,"soonestReadout":190},[186],{"nctId":187,"briefTitle":188,"status":163,"phases":189,"primaryCompletion":190,"completion":191,"start":192,"enrollment":193,"conditions":194,"interventions":196},"NCT05068830","Safety and Efficacy of Plasma Transfusion From Exercise-trained Donors in Patients With Early Alzheimer's Disease",[83],"2027-03-01","2031-03-01","2021-09-17",60,[195],"Alzheimer Disease",[178,197,198],"Octaplasma","Saline",{"trials":200,"activeCount":94},[],{"trials":202,"activeCount":94},[],{"trials":204,"activeCount":94},[],{"intervention":197,"totalTrials":149,"cells":206},{"EARLY_PHASE1":207,"PHASE1":209,"PHASE2":211,"PHASE3":217,"PHASE4":219,"NA":221},{"trials":208,"activeCount":94},[],{"trials":210,"activeCount":94},[],{"trials":212,"activeCount":149,"soonestReadout":190},[213],{"nctId":187,"briefTitle":188,"status":163,"phases":214,"primaryCompletion":190,"completion":191,"start":192,"enrollment":193,"conditions":215,"interventions":216},[83],[195],[178,197,198],{"trials":218,"activeCount":94},[],{"trials":220,"activeCount":94},[],{"trials":222,"activeCount":94},[],{"intervention":198,"totalTrials":149,"cells":224},{"EARLY_PHASE1":225,"PHASE1":227,"PHASE2":229,"PHASE3":235,"PHASE4":237,"NA":239},{"trials":226,"activeCount":94},[],{"trials":228,"activeCount":94},[],{"trials":230,"activeCount":149,"soonestReadout":190},[231],{"nctId":187,"briefTitle":188,"status":163,"phases":232,"primaryCompletion":190,"completion":191,"start":192,"enrollment":193,"conditions":233,"interventions":234},[83],[195],[178,197,198],{"trials":236,"activeCount":94},[],{"trials":238,"activeCount":94},[],{"trials":240,"activeCount":94},[],{"intervention":242,"totalTrials":243,"cells":244},"Blood samples",2,{"EARLY_PHASE1":245,"PHASE1":247,"PHASE2":249,"PHASE3":251,"PHASE4":253,"NA":255},{"trials":246,"activeCount":94},[],{"trials":248,"activeCount":94},[],{"trials":250,"activeCount":94},[],{"trials":252,"activeCount":94},[],{"trials":254,"activeCount":94},[],{"trials":256,"activeCount":243,"soonestReadout":274},[257,270],{"nctId":258,"briefTitle":259,"status":142,"phases":260,"primaryCompletion":261,"completion":261,"start":262,"enrollment":193,"conditions":263,"interventions":268},"NCT06448403","Multimodal Assesment of Alzheimer Patients",[],"2030-12-29","2024-07-01",[264,265,266,267],"Mild Cognitive Impairment","Alzheimer Disease, Late Onset","Cognitive Impairment","Dementia",[242,269],"Fecal samples",{"nctId":271,"briefTitle":272,"status":142,"phases":273,"primaryCompletion":274,"completion":274,"start":275,"enrollment":18,"conditions":276,"interventions":280},"NCT07118137","Memory Deterioration in Alzheimer Disease",[],"2027-12-31","2023-10-15",[195,277,278,279],"Neurodegenerative Diseases","Magnetic Resonance Imaging","Memory Impairment",[242,281],"Stool samples",{"intervention":283,"totalTrials":284,"cells":285},"Ibuprofen",3,{"EARLY_PHASE1":286,"PHASE1":288,"PHASE2":290,"PHASE3":292,"PHASE4":305,"NA":307},{"trials":287,"activeCount":94},[],{"trials":289,"activeCount":94},[],{"trials":291,"activeCount":94},[],{"trials":293,"activeCount":94},[294],{"nctId":295,"briefTitle":296,"status":102,"phases":297,"primaryCompletion":298,"completion":298,"start":299,"enrollment":300,"conditions":301,"interventions":304},"NCT02330926","Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy",[84],"2023-04","2015-04",221,[302,303],"Cachexia","Neoplasms",[283],{"trials":306,"activeCount":94},[],{"trials":308,"activeCount":149,"soonestReadout":58},[309,318],{"nctId":310,"briefTitle":311,"status":312,"phases":313,"primaryCompletion":314,"completion":314,"start":315,"enrollment":94,"conditions":316,"interventions":317},"NCT00258791","Effects of Pretreatment With Ibuprofen in Post-Electroconvulsive Therapy (ECT) Headache","WITHDRAWN",[86],"2012-05","2012-01",[26],[283],{"nctId":319,"briefTitle":320,"status":142,"phases":321,"primaryCompletion":58,"completion":58,"start":322,"enrollment":323,"conditions":324,"interventions":325},"NCT03476577","Bariatric Surgery and Pharmacokinetics of Ibuprofen",[],"2016-11-02",12,[15],[283],{"intervention":63,"totalTrials":243,"cells":327},{"EARLY_PHASE1":328,"PHASE1":330,"PHASE2":332,"PHASE3":334,"PHASE4":349,"NA":351},{"trials":329,"activeCount":94},[],{"trials":331,"activeCount":94},[],{"trials":333,"activeCount":94},[],{"trials":335,"activeCount":94},[336],{"nctId":337,"briefTitle":338,"status":102,"phases":339,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":347},"NCT00884663","Candesartan Versus Propranolol for Migraine Prevention",[83,84],"2012-03","2009-04",72,[344,345,346],"Migraine Without Aura","Migraine With Aura","Chronic Migraine",[63,348],"propranolol",{"trials":350,"activeCount":94},[],{"trials":352,"activeCount":149,"soonestReadout":58},[353],{"nctId":61,"briefTitle":62,"status":142,"phases":354,"primaryCompletion":58,"completion":58,"start":322,"enrollment":323,"conditions":355,"interventions":356},[],[15],[63],{"intervention":44,"totalTrials":149,"cells":358},{"EARLY_PHASE1":359,"PHASE1":361,"PHASE2":363,"PHASE3":365,"PHASE4":367,"NA":369},{"trials":360,"activeCount":94},[],{"trials":362,"activeCount":94},[],{"trials":364,"activeCount":94},[],{"trials":366,"activeCount":94},[],{"trials":368,"activeCount":94},[],{"trials":370,"activeCount":149,"soonestReadout":43},[371],{"nctId":41,"briefTitle":42,"status":163,"phases":372,"primaryCompletion":43,"completion":373,"start":374,"enrollment":375,"conditions":376,"interventions":379},[86],"2027-06","2018-09-18",106,[377,378],"Vulvodynia","Chronic Pain",[44,380],"Treatment as usual",{"intervention":380,"totalTrials":149,"cells":382},{"EARLY_PHASE1":383,"PHASE1":385,"PHASE2":387,"PHASE3":389,"PHASE4":391,"NA":393},{"trials":384,"activeCount":94},[],{"trials":386,"activeCount":94},[],{"trials":388,"activeCount":94},[],{"trials":390,"activeCount":94},[],{"trials":392,"activeCount":94},[],{"trials":394,"activeCount":149,"soonestReadout":43},[395],{"nctId":41,"briefTitle":42,"status":163,"phases":396,"primaryCompletion":43,"completion":373,"start":374,"enrollment":375,"conditions":397,"interventions":398},[86],[377,378],[44,380],{"intervention":400,"totalTrials":149,"cells":401},"Ramipril",{"EARLY_PHASE1":402,"PHASE1":404,"PHASE2":406,"PHASE3":408,"PHASE4":410,"NA":412},{"trials":403,"activeCount":94},[],{"trials":405,"activeCount":94},[],{"trials":407,"activeCount":94},[],{"trials":409,"activeCount":94},[],{"trials":411,"activeCount":94},[],{"trials":413,"activeCount":149,"soonestReadout":418},[414],{"nctId":415,"briefTitle":416,"status":142,"phases":417,"primaryCompletion":418,"completion":418,"start":419,"enrollment":323,"conditions":420,"interventions":421},"NCT03440177","Bariatric Surgery and Pharmacokinetics of Ramipril",[],"2026-12","2018-01-02",[15],[400],{"intervention":54,"totalTrials":149,"cells":423},{"EARLY_PHASE1":424,"PHASE1":426,"PHASE2":428,"PHASE3":430,"PHASE4":432,"NA":434},{"trials":425,"activeCount":94},[],{"trials":427,"activeCount":94},[],{"trials":429,"activeCount":94},[],{"trials":431,"activeCount":94},[],{"trials":433,"activeCount":94},[],{"trials":435,"activeCount":149,"soonestReadout":53},[436],{"nctId":51,"briefTitle":52,"status":142,"phases":437,"primaryCompletion":53,"completion":53,"start":438,"enrollment":323,"conditions":439,"interventions":440},[],"2016-11",[15],[54],{"intervention":59,"totalTrials":149,"cells":442},{"EARLY_PHASE1":443,"PHASE1":445,"PHASE2":447,"PHASE3":449,"PHASE4":451,"NA":453},{"trials":444,"activeCount":94},[],{"trials":446,"activeCount":94},[],{"trials":448,"activeCount":94},[],{"trials":450,"activeCount":94},[],{"trials":452,"activeCount":94},[],{"trials":454,"activeCount":149,"soonestReadout":58},[455],{"nctId":56,"briefTitle":57,"status":142,"phases":456,"primaryCompletion":58,"completion":58,"start":322,"enrollment":323,"conditions":457,"interventions":458},[],[15],[59],{"intervention":460,"totalTrials":149,"cells":461},"Apixaban",{"EARLY_PHASE1":462,"PHASE1":464,"PHASE2":466,"PHASE3":468,"PHASE4":470,"NA":472},{"trials":463,"activeCount":94},[],{"trials":465,"activeCount":94},[],{"trials":467,"activeCount":94},[],{"trials":469,"activeCount":94},[],{"trials":471,"activeCount":94},[],{"trials":473,"activeCount":149,"soonestReadout":418},[474],{"nctId":475,"briefTitle":476,"status":142,"phases":477,"primaryCompletion":418,"completion":418,"start":419,"enrollment":323,"conditions":478,"interventions":479},"NCT03448783","Bariatric Surgery and Pharmacokinetics of Apixaban",[],[15],[460],{"intervention":269,"totalTrials":149,"cells":481},{"EARLY_PHASE1":482,"PHASE1":484,"PHASE2":486,"PHASE3":488,"PHASE4":490,"NA":492},{"trials":483,"activeCount":94},[],{"trials":485,"activeCount":94},[],{"trials":487,"activeCount":94},[],{"trials":489,"activeCount":94},[],{"trials":491,"activeCount":94},[],{"trials":493,"activeCount":149,"soonestReadout":261},[494],{"nctId":258,"briefTitle":259,"status":142,"phases":495,"primaryCompletion":261,"completion":261,"start":262,"enrollment":193,"conditions":496,"interventions":497},[],[264,265,266,267],[242,269],{"intervention":67,"totalTrials":149,"cells":499},{"EARLY_PHASE1":500,"PHASE1":502,"PHASE2":504,"PHASE3":506,"PHASE4":508,"NA":510},{"trials":501,"activeCount":94},[],{"trials":503,"activeCount":94},[],{"trials":505,"activeCount":94},[],{"trials":507,"activeCount":94},[],{"trials":509,"activeCount":94},[],{"trials":511,"activeCount":149,"soonestReadout":58},[512],{"nctId":65,"briefTitle":66,"status":142,"phases":513,"primaryCompletion":58,"completion":58,"start":322,"enrollment":323,"conditions":514,"interventions":515},[],[15],[67],{"intervention":71,"totalTrials":149,"cells":517},{"EARLY_PHASE1":518,"PHASE1":520,"PHASE2":522,"PHASE3":524,"PHASE4":526,"NA":528},{"trials":519,"activeCount":94},[],{"trials":521,"activeCount":94},[],{"trials":523,"activeCount":94},[],{"trials":525,"activeCount":94},[],{"trials":527,"activeCount":94},[],{"trials":529,"activeCount":149,"soonestReadout":58},[530],{"nctId":69,"briefTitle":70,"status":142,"phases":531,"primaryCompletion":58,"completion":58,"start":322,"enrollment":323,"conditions":532,"interventions":533},[],[15],[71],{"intervention":75,"totalTrials":149,"cells":535},{"EARLY_PHASE1":536,"PHASE1":538,"PHASE2":540,"PHASE3":542,"PHASE4":544,"NA":546},{"trials":537,"activeCount":94},[],{"trials":539,"activeCount":94},[],{"trials":541,"activeCount":94},[],{"trials":543,"activeCount":94},[],{"trials":545,"activeCount":94},[],{"trials":547,"activeCount":149,"soonestReadout":58},[548],{"nctId":73,"briefTitle":74,"status":142,"phases":549,"primaryCompletion":58,"completion":58,"start":322,"enrollment":323,"conditions":550,"interventions":551},[],[15],[75],{"intervention":79,"totalTrials":149,"cells":553},{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":560,"PHASE4":562,"NA":564},{"trials":555,"activeCount":94},[],{"trials":557,"activeCount":94},[],{"trials":559,"activeCount":94},[],{"trials":561,"activeCount":94},[],{"trials":563,"activeCount":94},[],{"trials":565,"activeCount":149,"soonestReadout":58},[566],{"nctId":77,"briefTitle":78,"status":142,"phases":567,"primaryCompletion":58,"completion":58,"start":322,"enrollment":323,"conditions":568,"interventions":569},[],[15],[79],{"intervention":571,"totalTrials":149,"cells":572},"Venlafaxine",{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":577,"PHASE3":579,"PHASE4":581,"NA":583},{"trials":574,"activeCount":94},[],{"trials":576,"activeCount":94},[],{"trials":578,"activeCount":94},[],{"trials":580,"activeCount":94},[],{"trials":582,"activeCount":94},[],{"trials":584,"activeCount":149,"soonestReadout":58},[585],{"nctId":586,"briefTitle":587,"status":142,"phases":588,"primaryCompletion":58,"completion":58,"start":322,"enrollment":323,"conditions":589,"interventions":590},"NCT03532477","Bariatric Surgery and Pharmacokinetics of Venlafaxine",[],[15],[571],{"intervention":592,"totalTrials":149,"cells":593},"Enalapril",{"EARLY_PHASE1":594,"PHASE1":596,"PHASE2":598,"PHASE3":600,"PHASE4":602,"NA":604},{"trials":595,"activeCount":94},[],{"trials":597,"activeCount":94},[],{"trials":599,"activeCount":94},[],{"trials":601,"activeCount":94},[],{"trials":603,"activeCount":94},[],{"trials":605,"activeCount":149,"soonestReadout":58},[606],{"nctId":607,"briefTitle":608,"status":142,"phases":609,"primaryCompletion":58,"completion":58,"start":322,"enrollment":323,"conditions":610,"interventions":611},"NCT03460366","Bariatric Surgery and Pharmacokinetics of Enalapril",[],[15],[592],{"intervention":281,"totalTrials":149,"cells":613},{"EARLY_PHASE1":614,"PHASE1":616,"PHASE2":618,"PHASE3":620,"PHASE4":622,"NA":624},{"trials":615,"activeCount":94},[],{"trials":617,"activeCount":94},[],{"trials":619,"activeCount":94},[],{"trials":621,"activeCount":94},[],{"trials":623,"activeCount":94},[],{"trials":625,"activeCount":149,"soonestReadout":274},[626],{"nctId":271,"briefTitle":272,"status":142,"phases":627,"primaryCompletion":274,"completion":274,"start":275,"enrollment":18,"conditions":628,"interventions":629},[],[195,277,278,279],[242,281],{"intervention":631,"totalTrials":149,"cells":632},"Metoprolol",{"EARLY_PHASE1":633,"PHASE1":635,"PHASE2":637,"PHASE3":639,"PHASE4":641,"NA":643},{"trials":634,"activeCount":94},[],{"trials":636,"activeCount":94},[],{"trials":638,"activeCount":94},[],{"trials":640,"activeCount":94},[],{"trials":642,"activeCount":94},[],{"trials":644,"activeCount":149,"soonestReadout":58},[645],{"nctId":646,"briefTitle":647,"status":142,"phases":648,"primaryCompletion":58,"completion":58,"start":322,"enrollment":323,"conditions":649,"interventions":650},"NCT03519906","Bariatric Surgery and Pharmacokinetics of Metoprolol",[],[15],[631],{"intervention":652,"totalTrials":149,"cells":653},"Chlorprothixene",{"EARLY_PHASE1":654,"PHASE1":656,"PHASE2":658,"PHASE3":660,"PHASE4":662,"NA":664},{"trials":655,"activeCount":94},[],{"trials":657,"activeCount":94},[],{"trials":659,"activeCount":94},[],{"trials":661,"activeCount":94},[],{"trials":663,"activeCount":94},[],{"trials":665,"activeCount":149,"soonestReadout":418},[666],{"nctId":667,"briefTitle":668,"status":142,"phases":669,"primaryCompletion":418,"completion":418,"start":419,"enrollment":323,"conditions":670,"interventions":671},"NCT03449485","Bariatric Surgery and Pharmacokinetics of Chlorprothixene",[],[15],[652],{"intervention":673,"totalTrials":149,"cells":674},"Buprenorphine",{"EARLY_PHASE1":675,"PHASE1":677,"PHASE2":679,"PHASE3":681,"PHASE4":683,"NA":685},{"trials":676,"activeCount":94},[],{"trials":678,"activeCount":94},[],{"trials":680,"activeCount":94},[],{"trials":682,"activeCount":94},[],{"trials":684,"activeCount":94},[],{"trials":686,"activeCount":149,"soonestReadout":58},[687],{"nctId":688,"briefTitle":689,"status":142,"phases":690,"primaryCompletion":58,"completion":58,"start":322,"enrollment":323,"conditions":691,"interventions":692},"NCT03460314","Bariatric Surgery and Pharmacokinetics of Buprenorphine",[],[15],[673],{"intervention":694,"totalTrials":149,"cells":695},"Losartan",{"EARLY_PHASE1":696,"PHASE1":698,"PHASE2":700,"PHASE3":702,"PHASE4":704,"NA":706},{"trials":697,"activeCount":94},[],{"trials":699,"activeCount":94},[],{"trials":701,"activeCount":94},[],{"trials":703,"activeCount":94},[],{"trials":705,"activeCount":94},[],{"trials":707,"activeCount":149,"soonestReadout":58},[708],{"nctId":709,"briefTitle":710,"status":142,"phases":711,"primaryCompletion":58,"completion":58,"start":322,"enrollment":323,"conditions":712,"interventions":713},"NCT03519893","Bariatric Surgery and Pharmacokinetics of Losartan",[],[15],[694],{"intervention":715,"totalTrials":149,"cells":716},"Escitalopram",{"EARLY_PHASE1":717,"PHASE1":719,"PHASE2":721,"PHASE3":723,"PHASE4":725,"NA":727},{"trials":718,"activeCount":94},[],{"trials":720,"activeCount":94},[],{"trials":722,"activeCount":94},[],{"trials":724,"activeCount":94},[],{"trials":726,"activeCount":94},[],{"trials":728,"activeCount":149,"soonestReadout":58},[729],{"nctId":730,"briefTitle":731,"status":142,"phases":732,"primaryCompletion":58,"completion":58,"start":322,"enrollment":323,"conditions":733,"interventions":734},"NCT03460379","Bariatric Surgery and Pharmacokinetics of Escitalopram",[],[15],[715],{"intervention":736,"totalTrials":149,"cells":737},"Gabapentin",{"EARLY_PHASE1":738,"PHASE1":740,"PHASE2":742,"PHASE3":744,"PHASE4":746,"NA":748},{"trials":739,"activeCount":94},[],{"trials":741,"activeCount":94},[],{"trials":743,"activeCount":94},[],{"trials":745,"activeCount":94},[],{"trials":747,"activeCount":94},[],{"trials":749,"activeCount":149,"soonestReadout":58},[750],{"nctId":751,"briefTitle":752,"status":142,"phases":753,"primaryCompletion":58,"completion":58,"start":322,"enrollment":323,"conditions":754,"interventions":755},"NCT03476538","Bariatric Surgery and Pharmacokinetics of Gabapentin",[],[15],[736],{"intervention":757,"totalTrials":149,"cells":758},"Irbesartan",{"EARLY_PHASE1":759,"PHASE1":761,"PHASE2":763,"PHASE3":765,"PHASE4":767,"NA":769},{"trials":760,"activeCount":94},[],{"trials":762,"activeCount":94},[],{"trials":764,"activeCount":94},[],{"trials":766,"activeCount":94},[],{"trials":768,"activeCount":94},[],{"trials":770,"activeCount":149,"soonestReadout":58},[771],{"nctId":772,"briefTitle":773,"status":142,"phases":774,"primaryCompletion":58,"completion":58,"start":322,"enrollment":323,"conditions":775,"interventions":776},"NCT03476603","Bariatric Surgery and Pharmacokinetics of Irbesartan",[],[15],[757],{"intervention":778,"totalTrials":149,"cells":779},"Paracetamol",{"EARLY_PHASE1":780,"PHASE1":782,"PHASE2":784,"PHASE3":786,"PHASE4":788,"NA":790},{"trials":781,"activeCount":94},[],{"trials":783,"activeCount":94},[],{"trials":785,"activeCount":94},[],{"trials":787,"activeCount":94},[],{"trials":789,"activeCount":94},[],{"trials":791,"activeCount":149,"soonestReadout":58},[792],{"nctId":793,"briefTitle":794,"status":142,"phases":795,"primaryCompletion":58,"completion":58,"start":322,"enrollment":323,"conditions":796,"interventions":797},"NCT03538457","Bariatric Surgery and Pharmacokinetics of Paracetamol",[],[15],[778],{"intervention":799,"totalTrials":149,"cells":800},"Quetiapine",{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":807,"PHASE4":809,"NA":811},{"trials":802,"activeCount":94},[],{"trials":804,"activeCount":94},[],{"trials":806,"activeCount":94},[],{"trials":808,"activeCount":94},[],{"trials":810,"activeCount":94},[],{"trials":812,"activeCount":149,"soonestReadout":58},[813],{"nctId":814,"briefTitle":815,"status":142,"phases":816,"primaryCompletion":58,"completion":58,"start":419,"enrollment":323,"conditions":817,"interventions":818},"NCT03449472","Bariatric Surgery and Pharmacokinetics of Quetiapine",[],[15],[799],{"intervention":820,"totalTrials":149,"cells":821},"Aflurax",{"EARLY_PHASE1":822,"PHASE1":824,"PHASE2":826,"PHASE3":828,"PHASE4":830,"NA":844},{"trials":823,"activeCount":94},[],{"trials":825,"activeCount":94},[],{"trials":827,"activeCount":94},[],{"trials":829,"activeCount":94},[],{"trials":831,"activeCount":94},[832],{"nctId":833,"briefTitle":834,"status":102,"phases":835,"primaryCompletion":836,"completion":837,"start":838,"enrollment":839,"conditions":840,"interventions":842},"NCT00184522","On Demand Treatment of Reflux Disease",[85],"2004-11","2004-12","2002-08",82,[841],"Gastroesophageal Reflux",[820,843],"esomeprazole",{"trials":845,"activeCount":94},[],{"intervention":843,"totalTrials":149,"cells":847},{"EARLY_PHASE1":848,"PHASE1":850,"PHASE2":852,"PHASE3":854,"PHASE4":856,"NA":862},{"trials":849,"activeCount":94},[],{"trials":851,"activeCount":94},[],{"trials":853,"activeCount":94},[],{"trials":855,"activeCount":94},[],{"trials":857,"activeCount":94},[858],{"nctId":833,"briefTitle":834,"status":102,"phases":859,"primaryCompletion":836,"completion":837,"start":838,"enrollment":839,"conditions":860,"interventions":861},[85],[841],[820,843],{"trials":863,"activeCount":94},[],{"intervention":865,"totalTrials":149,"cells":866},"Imiquimod 5%",{"EARLY_PHASE1":867,"PHASE1":869,"PHASE2":871,"PHASE3":873,"PHASE4":875,"NA":888},{"trials":868,"activeCount":94},[],{"trials":870,"activeCount":94},[],{"trials":872,"activeCount":94},[],{"trials":874,"activeCount":94},[],{"trials":876,"activeCount":94},[877],{"nctId":878,"briefTitle":879,"status":102,"phases":880,"primaryCompletion":881,"completion":882,"start":883,"enrollment":884,"conditions":885,"interventions":887},"NCT00849992","Treatment Study for Actinic Cheilitis Comparing Imiquimod 5% and Photodynamic Therapy",[85],"2013-03","2013-11","2009-03",53,[886],"Actinic Cheilitis",[865],{"trials":889,"activeCount":94},[],{"intervention":891,"totalTrials":149,"cells":892},"Dihydrocodeine",{"EARLY_PHASE1":893,"PHASE1":895,"PHASE2":897,"PHASE3":899,"PHASE4":901,"NA":912},{"trials":894,"activeCount":94},[],{"trials":896,"activeCount":94},[],{"trials":898,"activeCount":94},[],{"trials":900,"activeCount":94},[],{"trials":902,"activeCount":94},[903],{"nctId":904,"briefTitle":905,"status":102,"phases":906,"primaryCompletion":907,"completion":907,"start":908,"enrollment":193,"conditions":909,"interventions":911},"NCT00547885","Randomized Controlled Double Blind Trial of Short vs Long Acting Dihydrocodeine in Chronic Non-malignant Pain",[85],"2012-06","2007-10",[910],"Pain",[891],{"trials":913,"activeCount":94},[],{"intervention":915,"totalTrials":149,"cells":916},"Seroxat, Cognitive therapy, Seroxat+ cognitive therapy",{"EARLY_PHASE1":917,"PHASE1":919,"PHASE2":921,"PHASE3":923,"PHASE4":925,"NA":938},{"trials":918,"activeCount":94},[],{"trials":920,"activeCount":94},[],{"trials":922,"activeCount":94},[],{"trials":924,"activeCount":94},[],{"trials":926,"activeCount":94},[927],{"nctId":928,"briefTitle":929,"status":102,"phases":930,"primaryCompletion":931,"completion":932,"start":933,"enrollment":934,"conditions":935,"interventions":937},"NCT00184106","RCT of Cognitive Therapy, Paroxetine, Combined CT and Paroxetine and Placebo",[85],"2009-12","2010-12","2004-10",86,[936],"Phobic Disorders",[915],{"trials":939,"activeCount":94},[],{"intervention":941,"totalTrials":149,"cells":942},"remifentanil and propofol",{"EARLY_PHASE1":943,"PHASE1":945,"PHASE2":947,"PHASE3":949,"PHASE4":951,"NA":964},{"trials":944,"activeCount":94},[],{"trials":946,"activeCount":94},[],{"trials":948,"activeCount":94},[],{"trials":950,"activeCount":94},[],{"trials":952,"activeCount":94},[953],{"nctId":954,"briefTitle":955,"status":102,"phases":956,"primaryCompletion":957,"completion":958,"start":959,"enrollment":193,"conditions":960,"interventions":962},"NCT00667043","Remifentanil and Propofol Versus Fentanyl and Midazolam for Sedation During Therapeutic Hypothermia. A Randomised, Controlled Trial",[85],"2009-05","2010-06","2008-04",[961],"Hypothermia",[941,963],"fentanyl and midazolam",{"trials":965,"activeCount":94},[],{"intervention":963,"totalTrials":149,"cells":967},{"EARLY_PHASE1":968,"PHASE1":970,"PHASE2":972,"PHASE3":974,"PHASE4":976,"NA":982},{"trials":969,"activeCount":94},[],{"trials":971,"activeCount":94},[],{"trials":973,"activeCount":94},[],{"trials":975,"activeCount":94},[],{"trials":977,"activeCount":94},[978],{"nctId":954,"briefTitle":955,"status":102,"phases":979,"primaryCompletion":957,"completion":958,"start":959,"enrollment":193,"conditions":980,"interventions":981},[85],[961],[941,963],{"trials":983,"activeCount":94},[],{"intervention":985,"totalTrials":149,"cells":986},"Povidone-Iodine 0.3%",{"EARLY_PHASE1":987,"PHASE1":989,"PHASE2":991,"PHASE3":993,"PHASE4":995,"NA":1009},{"trials":988,"activeCount":94},[],{"trials":990,"activeCount":94},[],{"trials":992,"activeCount":94},[],{"trials":994,"activeCount":94},[],{"trials":996,"activeCount":94},[997],{"nctId":998,"briefTitle":999,"status":1000,"phases":1001,"primaryCompletion":1002,"completion":1002,"start":1003,"enrollment":1004,"conditions":1005,"interventions":1007},"NCT04745663","Optimizing Preoperative Disinfection of Eyes","TERMINATED",[85],"2021-04-30","2021-02-08",150,[1006],"Eye Infections",[985,1008],"Povidone-Iodine 5%",{"trials":1010,"activeCount":94},[],{"intervention":1008,"totalTrials":149,"cells":1012},{"EARLY_PHASE1":1013,"PHASE1":1015,"PHASE2":1017,"PHASE3":1019,"PHASE4":1021,"NA":1027},{"trials":1014,"activeCount":94},[],{"trials":1016,"activeCount":94},[],{"trials":1018,"activeCount":94},[],{"trials":1020,"activeCount":94},[],{"trials":1022,"activeCount":94},[1023],{"nctId":998,"briefTitle":999,"status":1000,"phases":1024,"primaryCompletion":1002,"completion":1002,"start":1003,"enrollment":1004,"conditions":1025,"interventions":1026},[85],[1006],[985,1008],{"trials":1028,"activeCount":94},[],{"intervention":1030,"totalTrials":149,"cells":1031},"Metformin \u002F Placebo treatment for 4 months",{"EARLY_PHASE1":1032,"PHASE1":1034,"PHASE2":1036,"PHASE3":1038,"PHASE4":1040,"NA":1051},{"trials":1033,"activeCount":94},[],{"trials":1035,"activeCount":94},[],{"trials":1037,"activeCount":94},[],{"trials":1039,"activeCount":94},[],{"trials":1041,"activeCount":94},[1042],{"nctId":1043,"briefTitle":1044,"status":1000,"phases":1045,"primaryCompletion":1046,"completion":1047,"start":1048,"enrollment":1004,"conditions":1049,"interventions":1050},"NCT00159575","Metformin in Assisted Reproduction-MET-AR-study",[85],"2009-08","2010-04","2005-03",[31],[1030],{"trials":1052,"activeCount":94},[],{"intervention":1054,"totalTrials":149,"cells":1055},"Acetyl-L-carnitine",{"EARLY_PHASE1":1056,"PHASE1":1058,"PHASE2":1060,"PHASE3":1062,"PHASE4":1064,"NA":1076},{"trials":1057,"activeCount":94},[],{"trials":1059,"activeCount":94},[],{"trials":1061,"activeCount":94},[],{"trials":1063,"activeCount":94},[],{"trials":1065,"activeCount":94},[1066],{"nctId":1067,"briefTitle":1068,"status":102,"phases":1069,"primaryCompletion":1070,"completion":1071,"start":1072,"enrollment":342,"conditions":1073,"interventions":1075},"NCT01695317","Effect of Acetyl-L-carnitine in Migraine",[85],"2014-07","2014-09","2013-04",[1074],"Migraine",[1054],{"trials":1077,"activeCount":94},[],{"intervention":1079,"totalTrials":243,"cells":1080},"intranasal oxytocin spray",{"EARLY_PHASE1":1081,"PHASE1":1083,"PHASE2":1085,"PHASE3":1087,"PHASE4":1109,"NA":1111},{"trials":1082,"activeCount":94},[],{"trials":1084,"activeCount":94},[],{"trials":1086,"activeCount":94},[],{"trials":1088,"activeCount":94},[1089,1100],{"nctId":1090,"briefTitle":1091,"status":102,"phases":1092,"primaryCompletion":1093,"completion":1093,"start":1094,"enrollment":1095,"conditions":1096,"interventions":1099},"NCT03339024","Intranasal Oxytocin Effects in Alcohol Withdrawal and Dependence; Follow-up Study",[84],"2019-03-31","2017-11-01",38,[1097,1098],"Alcoholism","Substance-Related Disorders",[1079],{"nctId":1101,"briefTitle":1102,"status":102,"phases":1103,"primaryCompletion":1104,"completion":1104,"start":1105,"enrollment":1106,"conditions":1107,"interventions":1108},"NCT02903251","Oxytocin and Alcohol Withdrawal and Dependence",[84],"2018-01-22","2016-10",40,[1097,1098],[1079],{"trials":1110,"activeCount":94},[],{"trials":1112,"activeCount":94},[],{"intervention":1114,"totalTrials":243,"cells":1115},"Methadone",{"EARLY_PHASE1":1116,"PHASE1":1118,"PHASE2":1120,"PHASE3":1122,"PHASE4":1141,"NA":1143},{"trials":1117,"activeCount":94},[],{"trials":1119,"activeCount":94},[],{"trials":1121,"activeCount":94},[],{"trials":1123,"activeCount":94},[1124,1132],{"nctId":1125,"briefTitle":1126,"status":102,"phases":1127,"primaryCompletion":1048,"completion":1048,"start":1128,"enrollment":323,"conditions":1129,"interventions":1131},"NCT00356083","Opioid Rotation From Morphine to Methadone in Treatment of Non-malignant Pain",[84],"2004-01",[1130],"Non-malignant Chronic Pain",[1114],{"nctId":1133,"briefTitle":1134,"status":102,"phases":1135,"primaryCompletion":1136,"completion":1136,"start":1137,"enrollment":1138,"conditions":1139,"interventions":1140},"NCT00184496","Switching From Morphine to Methadone. A Clinical, Pharmacological and Pharmacogenetic Study",[84],"2009-09","2004-08",42,[33],[1114],{"trials":1142,"activeCount":94},[],{"trials":1144,"activeCount":94},[],{"intervention":348,"totalTrials":149,"cells":1146},{"EARLY_PHASE1":1147,"PHASE1":1149,"PHASE2":1151,"PHASE3":1153,"PHASE4":1159,"NA":1161},{"trials":1148,"activeCount":94},[],{"trials":1150,"activeCount":94},[],{"trials":1152,"activeCount":94},[],{"trials":1154,"activeCount":94},[1155],{"nctId":337,"briefTitle":338,"status":102,"phases":1156,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":1157,"interventions":1158},[83,84],[344,345,346],[63,348],{"trials":1160,"activeCount":94},[],{"trials":1162,"activeCount":94},[],{"intervention":1164,"totalTrials":149,"cells":1165},"Antibiotic",{"EARLY_PHASE1":1166,"PHASE1":1168,"PHASE2":1170,"PHASE3":1172,"PHASE4":1184,"NA":1186},{"trials":1167,"activeCount":94},[],{"trials":1169,"activeCount":94},[],{"trials":1171,"activeCount":94},[],{"trials":1173,"activeCount":94},[1174],{"nctId":1175,"briefTitle":1176,"status":102,"phases":1177,"primaryCompletion":1178,"completion":1178,"start":1179,"enrollment":1180,"conditions":1181,"interventions":1183},"NCT00934830","Antibiotics Versus Therapeutic Ultrasound for Sinusitis",[84],"2008-10","2005-01",48,[1182],"Sinusitis",[1164],{"trials":1185,"activeCount":94},[],{"trials":1187,"activeCount":94},[],{"intervention":1189,"totalTrials":149,"cells":1190},"Naloxone, intranasal",{"EARLY_PHASE1":1191,"PHASE1":1193,"PHASE2":1195,"PHASE3":1197,"PHASE4":1211,"NA":1213},{"trials":1192,"activeCount":94},[],{"trials":1194,"activeCount":94},[],{"trials":1196,"activeCount":94},[],{"trials":1198,"activeCount":94},[1199],{"nctId":1200,"briefTitle":1201,"status":102,"phases":1202,"primaryCompletion":1203,"completion":1203,"start":1204,"enrollment":1205,"conditions":1206,"interventions":1209},"NCT03518021","Naloxone Nasal Spray Compared With Naloxone Injection for Opioid Overdoses Outside the Hospital",[84],"2020-10-06","2018-05-15",286,[1207,1208],"Overdose","Drug Abuse",[1189,1210],"Naloxone, intramuscular",{"trials":1212,"activeCount":94},[],{"trials":1214,"activeCount":94},[],{"intervention":1210,"totalTrials":149,"cells":1216},{"EARLY_PHASE1":1217,"PHASE1":1219,"PHASE2":1221,"PHASE3":1223,"PHASE4":1229,"NA":1231},{"trials":1218,"activeCount":94},[],{"trials":1220,"activeCount":94},[],{"trials":1222,"activeCount":94},[],{"trials":1224,"activeCount":94},[1225],{"nctId":1200,"briefTitle":1201,"status":102,"phases":1226,"primaryCompletion":1203,"completion":1203,"start":1204,"enrollment":1205,"conditions":1227,"interventions":1228},[84],[1207,1208],[1189,1210],{"trials":1230,"activeCount":94},[],{"trials":1232,"activeCount":94},[],{"intervention":1234,"totalTrials":149,"cells":1235},"Chemo-immunotherapy",{"EARLY_PHASE1":1236,"PHASE1":1238,"PHASE2":1240,"PHASE3":1242,"PHASE4":1253,"NA":1255},{"trials":1237,"activeCount":94},[],{"trials":1239,"activeCount":94},[],{"trials":1241,"activeCount":94},[],{"trials":1243,"activeCount":94},[1244],{"nctId":1245,"briefTitle":1246,"status":1000,"phases":1247,"primaryCompletion":1248,"completion":1248,"start":1249,"enrollment":1250,"conditions":1251,"interventions":1252},"NCT05223647","Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer",[84],"2025-09-04","2022-01-11",239,[169],[1234],{"trials":1254,"activeCount":94},[],{"trials":1256,"activeCount":94},[],{"intervention":1258,"totalTrials":149,"cells":1259},"maintenance pemetrexed",{"EARLY_PHASE1":1260,"PHASE1":1262,"PHASE2":1264,"PHASE3":1266,"PHASE4":1279,"NA":1281},{"trials":1261,"activeCount":94},[],{"trials":1263,"activeCount":94},[],{"trials":1265,"activeCount":94},[],{"trials":1267,"activeCount":94},[1268],{"nctId":1269,"briefTitle":1270,"status":1000,"phases":1271,"primaryCompletion":1272,"completion":1272,"start":1273,"enrollment":1274,"conditions":1275,"interventions":1277},"NCT02004184","Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy",[84],"2018-03","2013-12",230,[1276],"Carcinoma, Non-small-cell Lung",[1258,1278],"pemetrexed at progression",{"trials":1280,"activeCount":94},[],{"trials":1282,"activeCount":94},[],{"intervention":1278,"totalTrials":149,"cells":1284},{"EARLY_PHASE1":1285,"PHASE1":1287,"PHASE2":1289,"PHASE3":1291,"PHASE4":1297,"NA":1299},{"trials":1286,"activeCount":94},[],{"trials":1288,"activeCount":94},[],{"trials":1290,"activeCount":94},[],{"trials":1292,"activeCount":94},[1293],{"nctId":1269,"briefTitle":1270,"status":1000,"phases":1294,"primaryCompletion":1272,"completion":1272,"start":1273,"enrollment":1274,"conditions":1295,"interventions":1296},[84],[1276],[1258,1278],{"trials":1298,"activeCount":94},[],{"trials":1300,"activeCount":94},[],{"intervention":1302,"totalTrials":149,"cells":1303},"single dose Morphine",{"EARLY_PHASE1":1304,"PHASE1":1306,"PHASE2":1308,"PHASE3":1310,"PHASE4":1323,"NA":1325},{"trials":1305,"activeCount":94},[],{"trials":1307,"activeCount":94},[],{"trials":1309,"activeCount":94},[],{"trials":1311,"activeCount":94},[1312],{"nctId":1313,"briefTitle":1314,"status":102,"phases":1315,"primaryCompletion":1316,"completion":1317,"start":1318,"enrollment":1319,"conditions":1320,"interventions":1321},"NCT00201539","Double Bedtime Dosing During Immediate-release Morphine Administration to Cancer Patients",[84],"2006-11","2008-02","2002-04",19,[33],[1302,1322],"double dose Morphine",{"trials":1324,"activeCount":94},[],{"trials":1326,"activeCount":94},[],{"intervention":1322,"totalTrials":149,"cells":1328},{"EARLY_PHASE1":1329,"PHASE1":1331,"PHASE2":1333,"PHASE3":1335,"PHASE4":1341,"NA":1343},{"trials":1330,"activeCount":94},[],{"trials":1332,"activeCount":94},[],{"trials":1334,"activeCount":94},[],{"trials":1336,"activeCount":94},[1337],{"nctId":1313,"briefTitle":1314,"status":102,"phases":1338,"primaryCompletion":1316,"completion":1317,"start":1318,"enrollment":1319,"conditions":1339,"interventions":1340},[84],[33],[1302,1322],{"trials":1342,"activeCount":94},[],{"trials":1344,"activeCount":94},[],{"intervention":1346,"totalTrials":149,"cells":1347},"thalidomide",{"EARLY_PHASE1":1348,"PHASE1":1350,"PHASE2":1352,"PHASE3":1354,"PHASE4":1366,"NA":1368},{"trials":1349,"activeCount":94},[],{"trials":1351,"activeCount":94},[],{"trials":1353,"activeCount":94},[],{"trials":1355,"activeCount":94},[1356],{"nctId":1357,"briefTitle":1358,"status":102,"phases":1359,"primaryCompletion":1360,"completion":1360,"start":1361,"enrollment":1362,"conditions":1363,"interventions":1365},"NCT00218855","Thalidomide to Patients With Previously Untreated Multiple Myeloma",[84],"2007-04","2002-01",363,[1364],"Multiple Myeloma",[1346],{"trials":1367,"activeCount":94},[],{"trials":1369,"activeCount":94},[],{"intervention":1371,"totalTrials":149,"cells":1372},"Ferric carboxymaltose",{"EARLY_PHASE1":1373,"PHASE1":1375,"PHASE2":1377,"PHASE3":1379,"PHASE4":1393,"NA":1395},{"trials":1374,"activeCount":94},[],{"trials":1376,"activeCount":94},[],{"trials":1378,"activeCount":94},[],{"trials":1380,"activeCount":94},[1381],{"nctId":1382,"briefTitle":1383,"status":1000,"phases":1384,"primaryCompletion":1385,"completion":1385,"start":1386,"enrollment":18,"conditions":1387,"interventions":1391},"NCT00929409","Controlled Randomised Trial of Ferric Carboxymaltose and Oral Iron to Treat Postpartum Anemia",[83,84],"2010-07","2009-06",[1388,1389,1390],"Anemia, Iron-Deficiency","Puerperal Disorders","Depression, Postpartum",[1371,1392],"Ferrous sulfate",{"trials":1394,"activeCount":94},[],{"trials":1396,"activeCount":94},[],{"intervention":1392,"totalTrials":149,"cells":1398},{"EARLY_PHASE1":1399,"PHASE1":1401,"PHASE2":1403,"PHASE3":1405,"PHASE4":1411,"NA":1413},{"trials":1400,"activeCount":94},[],{"trials":1402,"activeCount":94},[],{"trials":1404,"activeCount":94},[],{"trials":1406,"activeCount":94},[1407],{"nctId":1382,"briefTitle":1383,"status":1000,"phases":1408,"primaryCompletion":1385,"completion":1385,"start":1386,"enrollment":18,"conditions":1409,"interventions":1410},[83,84],[1388,1389,1390],[1371,1392],{"trials":1412,"activeCount":94},[],{"trials":1414,"activeCount":94},[],{"intervention":1416,"totalTrials":149,"cells":1417},"intranasal fentanyl spray",{"EARLY_PHASE1":1418,"PHASE1":1420,"PHASE2":1422,"PHASE3":1424,"PHASE4":1435,"NA":1437},{"trials":1419,"activeCount":94},[],{"trials":1421,"activeCount":94},[],{"trials":1423,"activeCount":94},[],{"trials":1425,"activeCount":94},[1426],{"nctId":1427,"briefTitle":1428,"status":312,"phases":1429,"primaryCompletion":1430,"completion":1430,"start":1431,"enrollment":94,"conditions":1432,"interventions":1433},"NCT01906073","Nasal Fentanyl for Chronic Cancer Pain",[84],"2020-12","2017-01",[33,910],[1416,1434],"slow release morphine",{"trials":1436,"activeCount":94},[],{"trials":1438,"activeCount":94},[],{"intervention":1434,"totalTrials":149,"cells":1440},{"EARLY_PHASE1":1441,"PHASE1":1443,"PHASE2":1445,"PHASE3":1447,"PHASE4":1453,"NA":1455},{"trials":1442,"activeCount":94},[],{"trials":1444,"activeCount":94},[],{"trials":1446,"activeCount":94},[],{"trials":1448,"activeCount":94},[1449],{"nctId":1427,"briefTitle":1428,"status":312,"phases":1450,"primaryCompletion":1430,"completion":1430,"start":1431,"enrollment":94,"conditions":1451,"interventions":1452},[84],[33,910],[1416,1434],{"trials":1454,"activeCount":94},[],{"trials":1456,"activeCount":94},[],{"intervention":1458,"totalTrials":149,"cells":1459},"Methylprednisolone",{"EARLY_PHASE1":1460,"PHASE1":1462,"PHASE2":1464,"PHASE3":1466,"PHASE4":1476,"NA":1478},{"trials":1461,"activeCount":94},[],{"trials":1463,"activeCount":94},[],{"trials":1465,"activeCount":94},[],{"trials":1467,"activeCount":94},[1468],{"nctId":1469,"briefTitle":1470,"status":102,"phases":1471,"primaryCompletion":1472,"completion":1472,"start":959,"enrollment":1473,"conditions":1474,"interventions":1475},"NCT00676936","Corticosteroids for Cancer Pain",[84],"2012-02",50,[33,910],[1458],{"trials":1477,"activeCount":94},[],{"trials":1479,"activeCount":94},[],{"intervention":1481,"totalTrials":243,"cells":1482},"Botulinum Toxin Type A 25 IU",{"EARLY_PHASE1":1483,"PHASE1":1485,"PHASE2":1487,"PHASE3":1507,"PHASE4":1509,"NA":1511},{"trials":1484,"activeCount":94},[],{"trials":1486,"activeCount":94},[],{"trials":1488,"activeCount":94},[1489,1498],{"nctId":1490,"briefTitle":1491,"status":102,"phases":1492,"primaryCompletion":1493,"completion":1493,"start":1494,"enrollment":21,"conditions":1495,"interventions":1496},"NCT03066635","Botulinum Toxin Type A Block of the Otic Ganglion in Chronic Cluster Headache: Safety Issues",[82,83],"2019-09-13","2017-04-18",[147],[1481,1497],"Botulinum Toxin Type A 12.5 IU",{"nctId":1499,"briefTitle":1500,"status":102,"phases":1501,"primaryCompletion":116,"completion":1502,"start":1503,"enrollment":21,"conditions":1504,"interventions":1505},"NCT02019017","Botox Injection in Treatment of Cluster Headache",[82,83],"2014-08","2013-10",[147],[1481,1506],"Botulinum Toxin Type A 50 IU",{"trials":1508,"activeCount":94},[],{"trials":1510,"activeCount":94},[],{"trials":1512,"activeCount":94},[],{"intervention":1514,"totalTrials":149,"cells":1515},"BoNT-A",{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1520,"PHASE3":1530,"PHASE4":1532,"NA":1534},{"trials":1517,"activeCount":94},[],{"trials":1519,"activeCount":94},[],{"trials":1521,"activeCount":94},[1522],{"nctId":1523,"briefTitle":1524,"status":102,"phases":1525,"primaryCompletion":1526,"completion":1526,"start":125,"enrollment":9,"conditions":1527,"interventions":1529},"NCT03543254","\"Follow the Sutures\". A New Procedure for Injection of Botulinum Toxin for Chronic Migraine",[83],"2021-01-01",[137,1528],"Chronic Disease",[1514],{"trials":1531,"activeCount":94},[],{"trials":1533,"activeCount":94},[],{"trials":1535,"activeCount":94},[],{"intervention":1537,"totalTrials":149,"cells":1538},"botox injection Multiguide",{"EARLY_PHASE1":1539,"PHASE1":1541,"PHASE2":1543,"PHASE3":1556,"PHASE4":1558,"NA":1560},{"trials":1540,"activeCount":94},[],{"trials":1542,"activeCount":94},[],{"trials":1544,"activeCount":94},[1545],{"nctId":1546,"briefTitle":1547,"status":102,"phases":1548,"primaryCompletion":1549,"completion":1550,"start":1105,"enrollment":1551,"conditions":1552,"interventions":1555},"NCT02784262","Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Rhinosinusitis With Nasal Polyposis",[83],"2018-09-04","2018-12",11,[1528,1553,1554],"Nasal Polyposis","Rhinitis",[1537],{"trials":1557,"activeCount":94},[],{"trials":1559,"activeCount":94},[],{"trials":1561,"activeCount":94},[],{"intervention":1497,"totalTrials":149,"cells":1563},{"EARLY_PHASE1":1564,"PHASE1":1566,"PHASE2":1568,"PHASE3":1574,"PHASE4":1576,"NA":1578},{"trials":1565,"activeCount":94},[],{"trials":1567,"activeCount":94},[],{"trials":1569,"activeCount":94},[1570],{"nctId":1490,"briefTitle":1491,"status":102,"phases":1571,"primaryCompletion":1493,"completion":1493,"start":1494,"enrollment":21,"conditions":1572,"interventions":1573},[82,83],[147],[1481,1497],{"trials":1575,"activeCount":94},[],{"trials":1577,"activeCount":94},[],{"trials":1579,"activeCount":94},[],{"intervention":1581,"totalTrials":149,"cells":1582},"Botulinum toxin",{"EARLY_PHASE1":1583,"PHASE1":1585,"PHASE2":1587,"PHASE3":1599,"PHASE4":1601,"NA":1603},{"trials":1584,"activeCount":94},[],{"trials":1586,"activeCount":94},[],{"trials":1588,"activeCount":94},[1589],{"nctId":1590,"briefTitle":1591,"status":102,"phases":1592,"primaryCompletion":931,"completion":931,"start":1593,"enrollment":1594,"conditions":1595,"interventions":1597},"NCT00184197","Botulinum Toxin Injection in Neck Muscles in Cervicogenic Headache",[83],"2005-05",28,[1596],"Cervicogenic Headache",[1581,1598],"Placebos",{"trials":1600,"activeCount":94},[],{"trials":1602,"activeCount":94},[],{"trials":1604,"activeCount":94},[],{"intervention":1598,"totalTrials":149,"cells":1606},{"EARLY_PHASE1":1607,"PHASE1":1609,"PHASE2":1611,"PHASE3":1617,"PHASE4":1619,"NA":1621},{"trials":1608,"activeCount":94},[],{"trials":1610,"activeCount":94},[],{"trials":1612,"activeCount":94},[1613],{"nctId":1590,"briefTitle":1591,"status":102,"phases":1614,"primaryCompletion":931,"completion":931,"start":1593,"enrollment":1594,"conditions":1615,"interventions":1616},[83],[1596],[1581,1598],{"trials":1618,"activeCount":94},[],{"trials":1620,"activeCount":94},[],{"trials":1622,"activeCount":94},[],{"intervention":1624,"totalTrials":149,"cells":1625},"Glycerol",{"EARLY_PHASE1":1626,"PHASE1":1628,"PHASE2":1630,"PHASE3":1639,"PHASE4":1641,"NA":1643},{"trials":1627,"activeCount":94},[],{"trials":1629,"activeCount":94},[],{"trials":1631,"activeCount":94},[1632],{"nctId":1633,"briefTitle":1634,"status":1000,"phases":1635,"primaryCompletion":1636,"completion":1636,"start":105,"enrollment":149,"conditions":1637,"interventions":1638},"NCT02624661","Glycerol Block of the Trigeminal Ganglion in Trigeminal Neuralgia Using a New Neuronavigation-based Surgical Technique",[82,83],"2019-01",[107,108],[1624],{"trials":1640,"activeCount":94},[],{"trials":1642,"activeCount":94},[],{"trials":1644,"activeCount":94},[],{"intervention":1646,"totalTrials":149,"cells":1647},"Imatinib",{"EARLY_PHASE1":1648,"PHASE1":1650,"PHASE2":1652,"PHASE3":1665,"PHASE4":1667,"NA":1669},{"trials":1649,"activeCount":94},[],{"trials":1651,"activeCount":94},[],{"trials":1653,"activeCount":94},[1654],{"nctId":1655,"briefTitle":1656,"status":102,"phases":1657,"primaryCompletion":1658,"completion":1659,"start":883,"enrollment":1660,"conditions":1661,"interventions":1663},"NCT00852566","Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia",[83],"2011-02","2015-12",46,[1662],"Chronic Myeloid Leukemia",[1646,1664],"Dasatinib",{"trials":1666,"activeCount":94},[],{"trials":1668,"activeCount":94},[],{"trials":1670,"activeCount":94},[],{"intervention":1664,"totalTrials":149,"cells":1672},{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1683,"PHASE4":1685,"NA":1687},{"trials":1674,"activeCount":94},[],{"trials":1676,"activeCount":94},[],{"trials":1678,"activeCount":94},[1679],{"nctId":1655,"briefTitle":1656,"status":102,"phases":1680,"primaryCompletion":1658,"completion":1659,"start":883,"enrollment":1660,"conditions":1681,"interventions":1682},[83],[1662],[1646,1664],{"trials":1684,"activeCount":94},[],{"trials":1686,"activeCount":94},[],{"trials":1688,"activeCount":94},[],{"intervention":1690,"totalTrials":149,"cells":1691},"Dasatinib + PegIFN",{"EARLY_PHASE1":1692,"PHASE1":1694,"PHASE2":1696,"PHASE3":1706,"PHASE4":1708,"NA":1710},{"trials":1693,"activeCount":94},[],{"trials":1695,"activeCount":94},[],{"trials":1697,"activeCount":94},[1698],{"nctId":1699,"briefTitle":1700,"status":102,"phases":1701,"primaryCompletion":105,"completion":105,"start":1702,"enrollment":1106,"conditions":1703,"interventions":1705},"NCT01725204","Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia",[83],"2012-09",[1704],"Leukemia, Myeloid, Chronic-Phase",[1690],{"trials":1707,"activeCount":94},[],{"trials":1709,"activeCount":94},[],{"trials":1711,"activeCount":94},[],{"intervention":1713,"totalTrials":149,"cells":1714},"candesartan cilexetil",{"EARLY_PHASE1":1715,"PHASE1":1717,"PHASE2":1719,"PHASE3":1727,"PHASE4":1729,"NA":1731},{"trials":1716,"activeCount":94},[],{"trials":1718,"activeCount":94},[],{"trials":1720,"activeCount":94},[1721],{"nctId":1722,"briefTitle":1723,"status":102,"phases":1724,"primaryCompletion":1386,"completion":931,"start":1048,"enrollment":1106,"conditions":1725,"interventions":1726},"NCT00184587","Prophylactic Treatment of Episodic Cluster Headache",[83],[147],[1713],{"trials":1728,"activeCount":94},[],{"trials":1730,"activeCount":94},[],{"trials":1732,"activeCount":94},[],{"intervention":119,"totalTrials":149,"cells":1734},{"EARLY_PHASE1":1735,"PHASE1":1737,"PHASE2":1739,"PHASE3":1745,"PHASE4":1747,"NA":1749},{"trials":1736,"activeCount":94},[],{"trials":1738,"activeCount":94},[],{"trials":1740,"activeCount":94},[1741],{"nctId":111,"briefTitle":112,"status":113,"phases":1742,"primaryCompletion":115,"completion":115,"start":116,"enrollment":9,"conditions":1743,"interventions":1744},[83],[15],[89,119],{"trials":1746,"activeCount":94},[],{"trials":1748,"activeCount":94},[],{"trials":1750,"activeCount":94},[],{"intervention":1506,"totalTrials":149,"cells":1752},{"EARLY_PHASE1":1753,"PHASE1":1755,"PHASE2":1757,"PHASE3":1763,"PHASE4":1765,"NA":1767},{"trials":1754,"activeCount":94},[],{"trials":1756,"activeCount":94},[],{"trials":1758,"activeCount":94},[1759],{"nctId":1499,"briefTitle":1500,"status":102,"phases":1760,"primaryCompletion":116,"completion":1502,"start":1503,"enrollment":21,"conditions":1761,"interventions":1762},[82,83],[147],[1481,1506],{"trials":1764,"activeCount":94},[],{"trials":1766,"activeCount":94},[],{"trials":1768,"activeCount":94},[],{"intervention":1770,"totalTrials":149,"cells":1771},"Sucrose",{"EARLY_PHASE1":1772,"PHASE1":1774,"PHASE2":1776,"PHASE3":1787,"PHASE4":1789,"NA":1791},{"trials":1773,"activeCount":94},[],{"trials":1775,"activeCount":94},[],{"trials":1777,"activeCount":94},[1778],{"nctId":1779,"briefTitle":1780,"status":102,"phases":1781,"primaryCompletion":1782,"completion":1782,"start":1179,"enrollment":1783,"conditions":1784,"interventions":1786},"NCT00218946","Nasogastric Tube in Premature Babies - Pain and Treatment",[83],"2007-08",24,[1785],"Infant, Premature",[1770],{"trials":1788,"activeCount":94},[],{"trials":1790,"activeCount":94},[],{"trials":1792,"activeCount":94},[],{"intervention":1794,"totalTrials":149,"cells":1795},"Intranasal naloxone",{"EARLY_PHASE1":1796,"PHASE1":1798,"PHASE2":1800,"PHASE3":1813,"PHASE4":1815,"NA":1817},{"trials":1797,"activeCount":94},[],{"trials":1799,"activeCount":94},[],{"trials":1801,"activeCount":94},[1802],{"nctId":1803,"briefTitle":1804,"status":102,"phases":1805,"primaryCompletion":299,"completion":1806,"start":1807,"enrollment":323,"conditions":1808,"interventions":1810},"NCT02307721","Pharmacokinetics and Pharmacodynamics of a New Formulation of Nasal Naloxone for Prehospital Use",[82,83],"2015-09","2014-12",[1809],"Drug Overdose",[1794,1811,1812],"Intramuscular naloxone","Remifentanil",{"trials":1814,"activeCount":94},[],{"trials":1816,"activeCount":94},[],{"trials":1818,"activeCount":94},[],{"intervention":1811,"totalTrials":149,"cells":1820},{"EARLY_PHASE1":1821,"PHASE1":1823,"PHASE2":1825,"PHASE3":1831,"PHASE4":1833,"NA":1835},{"trials":1822,"activeCount":94},[],{"trials":1824,"activeCount":94},[],{"trials":1826,"activeCount":94},[1827],{"nctId":1803,"briefTitle":1804,"status":102,"phases":1828,"primaryCompletion":299,"completion":1806,"start":1807,"enrollment":323,"conditions":1829,"interventions":1830},[82,83],[1809],[1794,1811,1812],{"trials":1832,"activeCount":94},[],{"trials":1834,"activeCount":94},[],{"trials":1836,"activeCount":94},[],{"intervention":1838,"totalTrials":149,"cells":1839},"recombinant human glutamic acid dehydrogenase (rhGAD65), formulated in aluminium hydrogel",{"EARLY_PHASE1":1840,"PHASE1":1842,"PHASE2":1844,"PHASE3":1857,"PHASE4":1859,"NA":1861},{"trials":1841,"activeCount":94},[],{"trials":1843,"activeCount":94},[],{"trials":1845,"activeCount":94},[1846],{"nctId":1847,"briefTitle":1848,"status":102,"phases":1849,"primaryCompletion":1850,"completion":1850,"start":1851,"enrollment":1852,"conditions":1853,"interventions":1855},"NCT04262479","Injections of Glutamic Acid Decarboxylase (GAD) for LADA Type of Diabetes",[83],"2022-05-05","2020-03-02",14,[1854],"Latent Autoimmune Diabetes in Adults",[1838,1856],"Vitamin D",{"trials":1858,"activeCount":94},[],{"trials":1860,"activeCount":94},[],{"trials":1862,"activeCount":94},[],{"intervention":1856,"totalTrials":149,"cells":1864},{"EARLY_PHASE1":1865,"PHASE1":1867,"PHASE2":1869,"PHASE3":1875,"PHASE4":1877,"NA":1879},{"trials":1866,"activeCount":94},[],{"trials":1868,"activeCount":94},[],{"trials":1870,"activeCount":94},[1871],{"nctId":1847,"briefTitle":1848,"status":102,"phases":1872,"primaryCompletion":1850,"completion":1850,"start":1851,"enrollment":1852,"conditions":1873,"interventions":1874},[83],[1854],[1838,1856],{"trials":1876,"activeCount":94},[],{"trials":1878,"activeCount":94},[],{"trials":1880,"activeCount":94},[],{"intervention":1882,"totalTrials":149,"cells":1883},"naloxone intranasal",{"EARLY_PHASE1":1884,"PHASE1":1886,"PHASE2":1888,"PHASE3":1900,"PHASE4":1902,"NA":1904},{"trials":1885,"activeCount":94},[],{"trials":1887,"activeCount":94},[],{"trials":1889,"activeCount":94},[1890],{"nctId":1891,"briefTitle":1892,"status":102,"phases":1893,"primaryCompletion":1894,"completion":1895,"start":1896,"enrollment":90,"conditions":1897,"interventions":1898},"NCT01939444","A Pilot Study of the Bioavailability of Nasal Naloxone",[83],"2014-10","2014-11","2013-08",[1809],[1882,1899],"naloxone intravenous",{"trials":1901,"activeCount":94},[],{"trials":1903,"activeCount":94},[],{"trials":1905,"activeCount":94},[],{"intervention":1899,"totalTrials":149,"cells":1907},{"EARLY_PHASE1":1908,"PHASE1":1910,"PHASE2":1912,"PHASE3":1918,"PHASE4":1920,"NA":1922},{"trials":1909,"activeCount":94},[],{"trials":1911,"activeCount":94},[],{"trials":1913,"activeCount":94},[1914],{"nctId":1891,"briefTitle":1892,"status":102,"phases":1915,"primaryCompletion":1894,"completion":1895,"start":1896,"enrollment":90,"conditions":1916,"interventions":1917},[83],[1809],[1882,1899],{"trials":1919,"activeCount":94},[],{"trials":1921,"activeCount":94},[],{"trials":1923,"activeCount":94},[],{"intervention":1925,"totalTrials":149,"cells":1926},"nasal naloxone",{"EARLY_PHASE1":1927,"PHASE1":1929,"PHASE2":1938,"PHASE3":1940,"PHASE4":1942,"NA":1944},{"trials":1928,"activeCount":94},[],{"trials":1930,"activeCount":94},[1931],{"nctId":1932,"briefTitle":1933,"status":102,"phases":1934,"primaryCompletion":1895,"completion":1895,"start":1935,"enrollment":323,"conditions":1936,"interventions":1937},"NCT02158117","Bioavailability of a New Formulation of Nasal Naloxone for Prehospital Use",[82],"2014-03",[1809],[1925],{"trials":1939,"activeCount":94},[],{"trials":1941,"activeCount":94},[],{"trials":1943,"activeCount":94},[],{"trials":1945,"activeCount":94},[],{"intervention":1947,"totalTrials":149,"cells":1948},"cognitive and hormone treatment",{"EARLY_PHASE1":1949,"PHASE1":1951,"PHASE2":1963,"PHASE3":1965,"PHASE4":1967,"NA":1969},{"trials":1950,"activeCount":94},[],{"trials":1952,"activeCount":94},[1953],{"nctId":1954,"briefTitle":1955,"status":1000,"phases":1956,"primaryCompletion":1957,"completion":1958,"start":1959,"enrollment":90,"conditions":1960,"interventions":1962},"NCT00379626","Cognitive and Hormonal Treatment of Sex Offenders",[82],"2008-08","2010-08","2003-08",[1961],"Paraphilia",[1947],{"trials":1964,"activeCount":94},[],{"trials":1966,"activeCount":94},[],{"trials":1968,"activeCount":94},[],{"trials":1970,"activeCount":94},[],{"intervention":1972,"totalTrials":149,"cells":1973},"Hydroxychloroquine",{"EARLY_PHASE1":1974,"PHASE1":1976,"PHASE2":1988,"PHASE3":1990,"PHASE4":1992,"NA":1994},{"trials":1975,"activeCount":94},[],{"trials":1977,"activeCount":94},[1978],{"nctId":1979,"briefTitle":1980,"status":102,"phases":1981,"primaryCompletion":1982,"completion":1982,"start":1983,"enrollment":1319,"conditions":1984,"interventions":1985},"NCT04163107","Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed\u002FRefractory Multiple Myeloma",[82],"2021-12-28","2020-01-07",[1364],[1972,1986,1987],"Carfilzomib","Dexamethasone",{"trials":1989,"activeCount":94},[],{"trials":1991,"activeCount":94},[],{"trials":1993,"activeCount":94},[],{"trials":1995,"activeCount":94},[],{"intervention":1986,"totalTrials":149,"cells":1997},{"EARLY_PHASE1":1998,"PHASE1":2000,"PHASE2":2006,"PHASE3":2008,"PHASE4":2010,"NA":2012},{"trials":1999,"activeCount":94},[],{"trials":2001,"activeCount":94},[2002],{"nctId":1979,"briefTitle":1980,"status":102,"phases":2003,"primaryCompletion":1982,"completion":1982,"start":1983,"enrollment":1319,"conditions":2004,"interventions":2005},[82],[1364],[1972,1986,1987],{"trials":2007,"activeCount":94},[],{"trials":2009,"activeCount":94},[],{"trials":2011,"activeCount":94},[],{"trials":2013,"activeCount":94},[],{"intervention":2015,"totalTrials":149,"cells":2016},"Intranasal (IN) naloxone 1x",{"EARLY_PHASE1":2017,"PHASE1":2019,"PHASE2":2032,"PHASE3":2034,"PHASE4":2036,"NA":2038},{"trials":2018,"activeCount":94},[],{"trials":2020,"activeCount":94},[2021],{"nctId":2022,"briefTitle":2023,"status":102,"phases":2024,"primaryCompletion":2025,"completion":2025,"start":134,"enrollment":2026,"conditions":2027,"interventions":2028},"NCT02598856","Bioavailability of Nasal Naloxone and Injected Naloxone Compared",[82],"2016-12",22,[1809],[2015,2029,2030,2031],"Intranasal (IN) naloxone 2","Intravenous (IV) naloxone","Intramuscular (IM) naloxone",{"trials":2033,"activeCount":94},[],{"trials":2035,"activeCount":94},[],{"trials":2037,"activeCount":94},[],{"trials":2039,"activeCount":94},[],{"intervention":2029,"totalTrials":149,"cells":2041},{"EARLY_PHASE1":2042,"PHASE1":2044,"PHASE2":2050,"PHASE3":2052,"PHASE4":2054,"NA":2056},{"trials":2043,"activeCount":94},[],{"trials":2045,"activeCount":94},[2046],{"nctId":2022,"briefTitle":2023,"status":102,"phases":2047,"primaryCompletion":2025,"completion":2025,"start":134,"enrollment":2026,"conditions":2048,"interventions":2049},[82],[1809],[2015,2029,2030,2031],{"trials":2051,"activeCount":94},[],{"trials":2053,"activeCount":94},[],{"trials":2055,"activeCount":94},[],{"trials":2057,"activeCount":94},[],{"intervention":2030,"totalTrials":149,"cells":2059},{"EARLY_PHASE1":2060,"PHASE1":2062,"PHASE2":2068,"PHASE3":2070,"PHASE4":2072,"NA":2074},{"trials":2061,"activeCount":94},[],{"trials":2063,"activeCount":94},[2064],{"nctId":2022,"briefTitle":2023,"status":102,"phases":2065,"primaryCompletion":2025,"completion":2025,"start":134,"enrollment":2026,"conditions":2066,"interventions":2067},[82],[1809],[2015,2029,2030,2031],{"trials":2069,"activeCount":94},[],{"trials":2071,"activeCount":94},[],{"trials":2073,"activeCount":94},[],{"trials":2075,"activeCount":94},[],{"intervention":2031,"totalTrials":149,"cells":2077},{"EARLY_PHASE1":2078,"PHASE1":2080,"PHASE2":2086,"PHASE3":2088,"PHASE4":2090,"NA":2092},{"trials":2079,"activeCount":94},[],{"trials":2081,"activeCount":94},[2082],{"nctId":2022,"briefTitle":2023,"status":102,"phases":2083,"primaryCompletion":2025,"completion":2025,"start":134,"enrollment":2026,"conditions":2084,"interventions":2085},[82],[1809],[2015,2029,2030,2031],{"trials":2087,"activeCount":94},[],{"trials":2089,"activeCount":94},[],{"trials":2091,"activeCount":94},[],{"trials":2093,"activeCount":94},[],{"intervention":2095,"totalTrials":2096,"cells":2097},"Metformin",4,{"EARLY_PHASE1":2098,"PHASE1":2100,"PHASE2":2102,"PHASE3":2112,"PHASE4":2130,"NA":2132},{"trials":2099,"activeCount":94},[],{"trials":2101,"activeCount":94},[],{"trials":2103,"activeCount":94},[2104],{"nctId":2105,"briefTitle":2106,"status":102,"phases":2107,"primaryCompletion":2108,"completion":2108,"start":2109,"enrollment":1106,"conditions":2110,"interventions":2111},"NCT03259919","Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome: a Pilot Study",[83],"2003-03","2000-10",[31],[2095],{"trials":2113,"activeCount":94},[2114,2123],{"nctId":2115,"briefTitle":2116,"status":102,"phases":2117,"primaryCompletion":2118,"completion":2118,"start":2119,"enrollment":2120,"conditions":2121,"interventions":2122},"NCT00159536","Metformin in Pregnant PCOS Women",[84],"2009-10","2005-02",257,[31],[2095],{"nctId":2124,"briefTitle":2125,"status":102,"phases":2126,"primaryCompletion":1046,"completion":2127,"start":1360,"enrollment":1180,"conditions":2128,"interventions":2129},"NCT00466622","Uterine Artery Blood Flow in Pregnant Women With PCOS Treated With Metformin",[84],"2010-02",[31],[2095],{"trials":2131,"activeCount":94},[],{"trials":2133,"activeCount":94},[2134],{"nctId":2135,"briefTitle":2136,"status":102,"phases":2137,"primaryCompletion":2138,"completion":2138,"start":2139,"enrollment":2140,"conditions":2141,"interventions":2143},"NCT01587378","Metformin to Prevent Late Miscarriage and Preterm Delivery in Women With Polycystic Ovary Syndrome",[86],"2017-10-31","2012-10",489,[2142,31],"Pregnancy",[2095],{"intervention":1812,"totalTrials":243,"cells":2145},{"EARLY_PHASE1":2146,"PHASE1":2148,"PHASE2":2150,"PHASE3":2156,"PHASE4":2158,"NA":2160},{"trials":2147,"activeCount":94},[],{"trials":2149,"activeCount":94},[],{"trials":2151,"activeCount":94},[2152],{"nctId":1803,"briefTitle":1804,"status":102,"phases":2153,"primaryCompletion":299,"completion":1806,"start":1807,"enrollment":323,"conditions":2154,"interventions":2155},[82,83],[1809],[1794,1811,1812],{"trials":2157,"activeCount":94},[],{"trials":2159,"activeCount":94},[],{"trials":2161,"activeCount":94},[2162],{"nctId":2163,"briefTitle":2164,"status":102,"phases":2165,"primaryCompletion":2166,"completion":2166,"start":299,"enrollment":323,"conditions":2167,"interventions":2168},"NCT02405988","Pharmacodynamics and Arteriovenous Differences of Naloxone in Healthy Participants Exposed to an Opioid",[86],"2016-02",[1809],[2169,1812],"Intravenous naloxone",{"intervention":1987,"totalTrials":243,"cells":2171},{"EARLY_PHASE1":2172,"PHASE1":2174,"PHASE2":2180,"PHASE3":2182,"PHASE4":2184,"NA":2186},{"trials":2173,"activeCount":94},[],{"trials":2175,"activeCount":94},[2176],{"nctId":1979,"briefTitle":1980,"status":102,"phases":2177,"primaryCompletion":1982,"completion":1982,"start":1983,"enrollment":1319,"conditions":2178,"interventions":2179},[82],[1364],[1972,1986,1987],{"trials":2181,"activeCount":94},[],{"trials":2183,"activeCount":94},[],{"trials":2185,"activeCount":94},[],{"trials":2187,"activeCount":94},[2188],{"nctId":2189,"briefTitle":2190,"status":102,"phases":2191,"primaryCompletion":931,"completion":932,"start":2192,"enrollment":2193,"conditions":2194,"interventions":2200},"NCT00476593","Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications",[86],"2005-09",218,[2195,2196,2197,2198,2199],"Uveitis","Iritis","Iridocyclitis","Anterior Uveitis","Macular Edema",[2201,1987],"Diclofenac",{"intervention":2169,"totalTrials":149,"cells":2203},{"EARLY_PHASE1":2204,"PHASE1":2206,"PHASE2":2208,"PHASE3":2210,"PHASE4":2212,"NA":2214},{"trials":2205,"activeCount":94},[],{"trials":2207,"activeCount":94},[],{"trials":2209,"activeCount":94},[],{"trials":2211,"activeCount":94},[],{"trials":2213,"activeCount":94},[],{"trials":2215,"activeCount":94},[2216],{"nctId":2163,"briefTitle":2164,"status":102,"phases":2217,"primaryCompletion":2166,"completion":2166,"start":299,"enrollment":323,"conditions":2218,"interventions":2219},[86],[1809],[2169,1812],{"intervention":2221,"totalTrials":149,"cells":2222},"efalizumab",{"EARLY_PHASE1":2223,"PHASE1":2225,"PHASE2":2227,"PHASE3":2229,"PHASE4":2231,"NA":2233},{"trials":2224,"activeCount":94},[],{"trials":2226,"activeCount":94},[],{"trials":2228,"activeCount":94},[],{"trials":2230,"activeCount":94},[],{"trials":2232,"activeCount":94},[],{"trials":2234,"activeCount":94},[2235],{"nctId":2236,"briefTitle":2237,"status":1000,"phases":2238,"primaryCompletion":2239,"completion":2240,"start":1593,"enrollment":2241,"conditions":2242,"interventions":2244},"NCT00184366","Classification and Characterization of Patients Treated With Efalizumab for Plaque Psoriasis",[],"2008-05","2008-07",96,[2243],"Plaque Psoriasis",[2221],{"intervention":2246,"totalTrials":149,"cells":2247},"gene sequencing",{"EARLY_PHASE1":2248,"PHASE1":2250,"PHASE2":2252,"PHASE3":2254,"PHASE4":2256,"NA":2258},{"trials":2249,"activeCount":94},[],{"trials":2251,"activeCount":94},[],{"trials":2253,"activeCount":94},[],{"trials":2255,"activeCount":94},[],{"trials":2257,"activeCount":94},[],{"trials":2259,"activeCount":94},[2260],{"nctId":2261,"briefTitle":2262,"status":102,"phases":2263,"primaryCompletion":2264,"completion":2264,"start":2265,"enrollment":1852,"conditions":2266,"interventions":2268},"NCT01904630","Sequencing to Identify Gene Variants in Familial Colorectal Cancer",[],"2016-06","2012-12",[2267],"Colorectal Cancer",[2246],{"intervention":2270,"totalTrials":149,"cells":2271},"Betablockers or other preventive drugs based on primary headache type",{"EARLY_PHASE1":2272,"PHASE1":2274,"PHASE2":2276,"PHASE3":2278,"PHASE4":2280,"NA":2282},{"trials":2273,"activeCount":94},[],{"trials":2275,"activeCount":94},[],{"trials":2277,"activeCount":94},[],{"trials":2279,"activeCount":94},[],{"trials":2281,"activeCount":94},[],{"trials":2283,"activeCount":94},[2284],{"nctId":2285,"briefTitle":2286,"status":102,"phases":2287,"primaryCompletion":1316,"completion":2288,"start":1128,"enrollment":2289,"conditions":2290,"interventions":2292},"NCT00159588","Medication-overuse Headache (MOH): Withdrawal or Use of Preventative Medications Directly?",[86],"2007-12",64,[2291],"Headache",[2270],{"intervention":2201,"totalTrials":149,"cells":2294},{"EARLY_PHASE1":2295,"PHASE1":2297,"PHASE2":2299,"PHASE3":2301,"PHASE4":2303,"NA":2305},{"trials":2296,"activeCount":94},[],{"trials":2298,"activeCount":94},[],{"trials":2300,"activeCount":94},[],{"trials":2302,"activeCount":94},[],{"trials":2304,"activeCount":94},[],{"trials":2306,"activeCount":94},[2307],{"nctId":2189,"briefTitle":2190,"status":102,"phases":2308,"primaryCompletion":931,"completion":932,"start":2192,"enrollment":2193,"conditions":2309,"interventions":2310},[86],[2195,2196,2197,2198,2199],[2201,1987],{"intervention":2312,"totalTrials":149,"cells":2313},"MAL-PDT re-treatment",{"EARLY_PHASE1":2314,"PHASE1":2316,"PHASE2":2318,"PHASE3":2320,"PHASE4":2322,"NA":2324},{"trials":2315,"activeCount":94},[],{"trials":2317,"activeCount":94},[],{"trials":2319,"activeCount":94},[],{"trials":2321,"activeCount":94},[],{"trials":2323,"activeCount":94},[],{"trials":2325,"activeCount":94},[2326],{"nctId":2327,"briefTitle":2328,"status":102,"phases":2329,"primaryCompletion":2330,"completion":2330,"start":907,"enrollment":2331,"conditions":2332,"interventions":2335},"NCT01482104","New Versus Approved Methyl-aminolevulinate Photodynamic Therapy (MAL-PDT) Regime in Basal Cell Carcinoma (BCC)",[86],"2017-10",277,[2333,2334],"Skin Neoplasms","Carcinoma, Basal Cell",[2312,2336],"usual MAL-PDT",{"intervention":2336,"totalTrials":149,"cells":2338},{"EARLY_PHASE1":2339,"PHASE1":2341,"PHASE2":2343,"PHASE3":2345,"PHASE4":2347,"NA":2349},{"trials":2340,"activeCount":94},[],{"trials":2342,"activeCount":94},[],{"trials":2344,"activeCount":94},[],{"trials":2346,"activeCount":94},[],{"trials":2348,"activeCount":94},[],{"trials":2350,"activeCount":94},[2351],{"nctId":2327,"briefTitle":2328,"status":102,"phases":2352,"primaryCompletion":2330,"completion":2330,"start":907,"enrollment":2331,"conditions":2353,"interventions":2354},[86],[2333,2334],[2312,2336],{"intervention":2356,"totalTrials":149,"cells":2357},"Dexamphetamine",{"EARLY_PHASE1":2358,"PHASE1":2360,"PHASE2":2362,"PHASE3":2364,"PHASE4":2366,"NA":2368},{"trials":2359,"activeCount":94},[],{"trials":2361,"activeCount":94},[],{"trials":2363,"activeCount":94},[],{"trials":2365,"activeCount":94},[],{"trials":2367,"activeCount":94},[],{"trials":2369,"activeCount":94},[2370],{"nctId":2371,"briefTitle":2372,"status":102,"phases":2373,"primaryCompletion":2374,"completion":2374,"start":322,"enrollment":323,"conditions":2375,"interventions":2376},"NCT03460353","Bariatric Surgery and Pharmacokinetics of Dexamphetamine",[],"2018-06-04",[15],[2356],{"intervention":2378,"totalTrials":149,"cells":2379},"Atomoxetine",{"EARLY_PHASE1":2380,"PHASE1":2382,"PHASE2":2384,"PHASE3":2386,"PHASE4":2388,"NA":2390},{"trials":2381,"activeCount":94},[],{"trials":2383,"activeCount":94},[],{"trials":2385,"activeCount":94},[],{"trials":2387,"activeCount":94},[],{"trials":2389,"activeCount":94},[],{"trials":2391,"activeCount":94},[2392],{"nctId":2393,"briefTitle":2394,"status":102,"phases":2395,"primaryCompletion":2396,"completion":2396,"start":322,"enrollment":323,"conditions":2397,"interventions":2398},"NCT03460210","Bariatric Surgery and Pharmacokinetics of Atomoxetine",[],"2020-03-03",[15],[2378],{"intervention":2400,"totalTrials":149,"cells":2401},"Budesonide",{"EARLY_PHASE1":2402,"PHASE1":2404,"PHASE2":2406,"PHASE3":2408,"PHASE4":2410,"NA":2412},{"trials":2403,"activeCount":94},[],{"trials":2405,"activeCount":94},[],{"trials":2407,"activeCount":94},[],{"trials":2409,"activeCount":94},[],{"trials":2411,"activeCount":94},[],{"trials":2413,"activeCount":94},[2414],{"nctId":2415,"briefTitle":2416,"status":1000,"phases":2417,"primaryCompletion":2418,"completion":1894,"start":2419,"enrollment":2420,"conditions":2421,"interventions":2423},"NCT00184171","Treatment of Microscopic Colitis",[86],"2010-09","2001-11",105,[2422],"Colitis",[2400,2424,2425],"Bismuth","Fiber",{"intervention":2424,"totalTrials":149,"cells":2427},{"EARLY_PHASE1":2428,"PHASE1":2430,"PHASE2":2432,"PHASE3":2434,"PHASE4":2436,"NA":2438},{"trials":2429,"activeCount":94},[],{"trials":2431,"activeCount":94},[],{"trials":2433,"activeCount":94},[],{"trials":2435,"activeCount":94},[],{"trials":2437,"activeCount":94},[],{"trials":2439,"activeCount":94},[2440],{"nctId":2415,"briefTitle":2416,"status":1000,"phases":2441,"primaryCompletion":2418,"completion":1894,"start":2419,"enrollment":2420,"conditions":2442,"interventions":2443},[86],[2422],[2400,2424,2425],{"intervention":2425,"totalTrials":149,"cells":2445},{"EARLY_PHASE1":2446,"PHASE1":2448,"PHASE2":2450,"PHASE3":2452,"PHASE4":2454,"NA":2456},{"trials":2447,"activeCount":94},[],{"trials":2449,"activeCount":94},[],{"trials":2451,"activeCount":94},[],{"trials":2453,"activeCount":94},[],{"trials":2455,"activeCount":94},[],{"trials":2457,"activeCount":94},[2458],{"nctId":2415,"briefTitle":2416,"status":1000,"phases":2459,"primaryCompletion":2418,"completion":1894,"start":2419,"enrollment":2420,"conditions":2460,"interventions":2461},[86],[2422],[2400,2424,2425],{"intervention":2463,"totalTrials":149,"cells":2464},"Methylphenidate",{"EARLY_PHASE1":2465,"PHASE1":2467,"PHASE2":2469,"PHASE3":2471,"PHASE4":2473,"NA":2475},{"trials":2466,"activeCount":94},[],{"trials":2468,"activeCount":94},[],{"trials":2470,"activeCount":94},[],{"trials":2472,"activeCount":94},[],{"trials":2474,"activeCount":94},[],{"trials":2476,"activeCount":94},[2477],{"nctId":2478,"briefTitle":2479,"status":102,"phases":2480,"primaryCompletion":2481,"completion":2481,"start":419,"enrollment":149,"conditions":2482,"interventions":2483},"NCT03440190","Bariatric Surgery and Pharmacokinetics of Methylphenidate",[],"2021-06-25",[15],[2463],{"intervention":2485,"totalTrials":149,"cells":2486},"metformin+ NPH insulin",{"EARLY_PHASE1":2487,"PHASE1":2489,"PHASE2":2491,"PHASE3":2493,"PHASE4":2495,"NA":2497},{"trials":2488,"activeCount":94},[],{"trials":2490,"activeCount":94},[],{"trials":2492,"activeCount":94},[],{"trials":2494,"activeCount":94},[],{"trials":2496,"activeCount":94},[],{"trials":2498,"activeCount":94},[2499],{"nctId":2500,"briefTitle":2501,"status":102,"phases":2502,"primaryCompletion":2503,"completion":2503,"start":883,"enrollment":2289,"conditions":2504,"interventions":2506},"NCT01140438","Treatment of Latent Autoimmune Diabetes of the Adult",[86],"2018-11",[2505],"Diabetes",[2485,2507],"metformin + sitagliptin +\u002F- repaglinide",{"intervention":2507,"totalTrials":149,"cells":2509},{"EARLY_PHASE1":2510,"PHASE1":2512,"PHASE2":2514,"PHASE3":2516,"PHASE4":2518,"NA":2520},{"trials":2511,"activeCount":94},[],{"trials":2513,"activeCount":94},[],{"trials":2515,"activeCount":94},[],{"trials":2517,"activeCount":94},[],{"trials":2519,"activeCount":94},[],{"trials":2521,"activeCount":94},[2522],{"nctId":2500,"briefTitle":2501,"status":102,"phases":2523,"primaryCompletion":2503,"completion":2503,"start":883,"enrollment":2289,"conditions":2524,"interventions":2525},[86],[2505],[2485,2507],{"intervention":2527,"totalTrials":149,"cells":2528},"Strattera",{"EARLY_PHASE1":2529,"PHASE1":2531,"PHASE2":2533,"PHASE3":2535,"PHASE4":2537,"NA":2539},{"trials":2530,"activeCount":94},[],{"trials":2532,"activeCount":94},[],{"trials":2534,"activeCount":94},[],{"trials":2536,"activeCount":94},[],{"trials":2538,"activeCount":94},[],{"trials":2540,"activeCount":94},[2541],{"nctId":2542,"briefTitle":2543,"status":102,"phases":2544,"primaryCompletion":2545,"completion":2545,"start":2546,"enrollment":1106,"conditions":2547,"interventions":2549},"NCT00356070","Treatment of Prisoners With Attention Deficit Hyperactive Disorder in Trondheim Prison",[86],"2006-12","2006-01",[2548],"Attention Deficit Hyperactivity Disorder",[2527],{"intervention":2551,"totalTrials":149,"cells":2552},"Iodixanol",{"EARLY_PHASE1":2553,"PHASE1":2555,"PHASE2":2557,"PHASE3":2559,"PHASE4":2561,"NA":2563},{"trials":2554,"activeCount":94},[],{"trials":2556,"activeCount":94},[],{"trials":2558,"activeCount":94},[],{"trials":2560,"activeCount":94},[],{"trials":2562,"activeCount":94},[],{"trials":2564,"activeCount":94},[2565],{"nctId":2566,"briefTitle":2567,"status":102,"phases":2568,"primaryCompletion":2569,"completion":958,"start":1957,"enrollment":9,"conditions":2570,"interventions":2572},"NCT01146639","DynaCT in Preoperative Imaging Before Insertion of Stentgraft",[86],"2010-05",[2571],"Abdominal Aortic Aneurysm",[2551],{"intervention":2574,"totalTrials":149,"cells":2575},"Lisdexamfetamine Dimesylate",{"EARLY_PHASE1":2576,"PHASE1":2578,"PHASE2":2580,"PHASE3":2582,"PHASE4":2584,"NA":2586},{"trials":2577,"activeCount":94},[],{"trials":2579,"activeCount":94},[],{"trials":2581,"activeCount":94},[],{"trials":2583,"activeCount":94},[],{"trials":2585,"activeCount":94},[],{"trials":2587,"activeCount":94},[2588],{"nctId":2589,"briefTitle":2590,"status":102,"phases":2591,"primaryCompletion":2592,"completion":2592,"start":322,"enrollment":323,"conditions":2593,"interventions":2594},"NCT03497169","Bariatric Surgery and Pharmacokinetics of Lisdexamphetamine",[],"2020-09-28",[15],[2574],{"intervention":2596,"totalTrials":149,"cells":2597},"Aflibercept",{"EARLY_PHASE1":2598,"PHASE1":2600,"PHASE2":2602,"PHASE3":2604,"PHASE4":2606,"NA":2608},{"trials":2599,"activeCount":94},[],{"trials":2601,"activeCount":94},[],{"trials":2603,"activeCount":94},[],{"trials":2605,"activeCount":94},[],{"trials":2607,"activeCount":94},[],{"trials":2609,"activeCount":94},[2610],{"nctId":2611,"briefTitle":2612,"status":1000,"phases":2613,"primaryCompletion":1806,"completion":1806,"start":116,"enrollment":24,"conditions":2614,"interventions":2617},"NCT01746875","A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes",[86],[2615,2616],"Macular Degeneration","Retinal Detachment",[2596,2618],"Verteporfin",{"intervention":2618,"totalTrials":149,"cells":2620},{"EARLY_PHASE1":2621,"PHASE1":2623,"PHASE2":2625,"PHASE3":2627,"PHASE4":2629,"NA":2631},{"trials":2622,"activeCount":94},[],{"trials":2624,"activeCount":94},[],{"trials":2626,"activeCount":94},[],{"trials":2628,"activeCount":94},[],{"trials":2630,"activeCount":94},[],{"trials":2632,"activeCount":94},[2633],{"nctId":2611,"briefTitle":2612,"status":1000,"phases":2634,"primaryCompletion":1806,"completion":1806,"start":116,"enrollment":24,"conditions":2635,"interventions":2636},[86],[2615,2616],[2596,2618]]